[
  {
    "ts": null,
    "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of Jan 11",
    "summary": "Dividend Champion, Contender, And Challenger Highlights: Week Of Jan 11",
    "url": "https://finnhub.io/api/news?id=24cd194a3a20b8e0867da9447639c2a8763dc564d568cdccc20d2e295e9e3b46",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767981556,
      "headline": "Dividend Champion, Contender, And Challenger Highlights: Week Of Jan 11",
      "id": 138050125,
      "image": "",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=24cd194a3a20b8e0867da9447639c2a8763dc564d568cdccc20d2e295e9e3b46"
    }
  },
  {
    "ts": null,
    "headline": "Assessing Abbott Laboratories (ABT) Valuation After Libre Assist Expands Its Digital Diabetes Offering",
    "summary": "Abbott Laboratories (ABT) has drawn fresh attention after unveiling Libre Assist, an AI driven feature in its Libre app that offers real time meal guidance for U.S. diabetes patients using continuous glucose data. See our latest analysis for Abbott Laboratories. The Libre Assist launch comes as Abbott’s 1 month share price return sits at 4.07% and its year to date share price return is 1.60%, while the 1 year total shareholder return of 12.53% points to steady momentum rather than a sharp re...",
    "url": "https://finnhub.io/api/news?id=7438bd3f2bed1cf14f9a8bea8a1a53ac248c12800216a8794b27868f6f9843d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767935503,
      "headline": "Assessing Abbott Laboratories (ABT) Valuation After Libre Assist Expands Its Digital Diabetes Offering",
      "id": 138043204,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (ABT) has drawn fresh attention after unveiling Libre Assist, an AI driven feature in its Libre app that offers real time meal guidance for U.S. diabetes patients using continuous glucose data. See our latest analysis for Abbott Laboratories. The Libre Assist launch comes as Abbott’s 1 month share price return sits at 4.07% and its year to date share price return is 1.60%, while the 1 year total shareholder return of 12.53% points to steady momentum rather than a sharp re...",
      "url": "https://finnhub.io/api/news?id=7438bd3f2bed1cf14f9a8bea8a1a53ac248c12800216a8794b27868f6f9843d7"
    }
  }
]